Chiasma, Inc. announced the appointment of William H. Ludlam, M.D., Ph.D., as vice president of medical affairs, effective August 26, 2015. Dr. Ludlam, a highly-regarded academic leader in the pituitary and rare disease space, comes to Chiasma after spending the last four years at Novartis Pharmaceuticals, where he served most recently as Senior Medical Director for the U.S. Clinical Development and Medical Affairs (USCDMA), Pituitary Disorders, Rare Diseases Franchise. In his role at Chiasma, Dr. Ludlam will be responsible for developing strategy around clinical and technical information to support the planned commercial launch of Mycapssa for the maintenance treatment of adults with acromegaly.

He will also lead all medical review activities around the Company's product education campaign, including its presence at key scientific events.